The Staff of the Division of Corporation Finance at the Securities and Exchange Commission (SEC) has recently begun issuing comment letters in the life sciences reverse merger (RM) context that involve a broadened...more
1/22/2024
/ Capital Formation ,
Compliance ,
Form 8-K ,
Form S-1 ,
Life Sciences ,
Mergers ,
Publicly-Traded Companies ,
Recapitalization ,
Resales Agreements ,
Reverse Mergers ,
Rule 144 ,
SEC Comment Letter Process ,
Securities and Exchange Commission (SEC) ,
Shell Corporations
On October 10, 2023, the US Securities and Exchange Commission (the “SEC”) adopted rule amendments governing beneficial ownership reporting under Sections 13(d) and 13(g) of the Securities Exchange Act of 1934 (the “Exchange...more
10/23/2023
/ Amended Rules ,
Beneficial Owner ,
Compliance ,
Compliance Dates ,
Corporate Governance ,
EDGAR ,
Publicly-Traded Companies ,
Reporting Requirements ,
Schedule 13D ,
Schedule 13G ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act
On December 14, 2022, the Securities and Exchange Commission unanimously adopted final rules relating to Rule 10b5-1 plans. Properly structured, a Rule 10b5-1 plan provides an affirmative defense to Rule 10b-5 liability for...more